Linked Life Data

21081243

Source:http://linkedlifedata.com/resource/pubmed/id/21081243

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2011-6-20
pubmed:databankReference
pubmed:abstractText
Highly active antiretroviral therapy (HAART)-induced lipoatrophy is characterized by hypoleptinemia and insulin resistance. Evidence suggests that pioglitazone and recombinant methionyl human leptin (metreleptin) administration has beneficial effects in human immunodeficiency virus (HIV)-infected lipoatrophic patients. This proof-of-concept study aimed at evaluating whether the combination of metreleptin and pioglitazone has favorable effects, above and beyond pioglitazone alone, on both metabolic outcomes and peripheral lipoatrophy in HIV-infected patients on HAART. Nine HIV-positive men with at least 6 months of HAART exposure, clinical evidence of lipoatrophy, and low leptin concentrations (?4 ng/mL) were placed on pioglitazone treatment (30 mg/d per os) and were randomized to receive either metreleptin (0.04 mg/kg subcutaneously once daily; n = 5) or placebo (n = 4) for 3 months in a double-blinded fashion. Compared with placebo, metreleptin reduced fasting serum insulin concentration, increased adiponectin concentration, reduced the homeostasis model assessment index of insulin resistance, and attenuated postprandial glycemia in response to a mixed meal (all P ? .02), but did not affect trunk and peripheral fat mass. HIV control was not affected, and no major adverse effects were observed. Metreleptin administration in HIV-positive, leptin-deficient patients with lipoatrophy treated with pioglitazone improves postprandial glycemia and insulin sensitivity. Results from this pilot study should be confirmed in larger clinical trials.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1532-8600
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 Elsevier Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1045-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:21081243-Adiponectin, pubmed-meshheading:21081243-Adult, pubmed-meshheading:21081243-Antiretroviral Therapy, Highly Active, pubmed-meshheading:21081243-Blood Glucose, pubmed-meshheading:21081243-Body Mass Index, pubmed-meshheading:21081243-Drug Therapy, Combination, pubmed-meshheading:21081243-HIV-1, pubmed-meshheading:21081243-HIV-Associated Lipodystrophy Syndrome, pubmed-meshheading:21081243-Humans, pubmed-meshheading:21081243-Hypoglycemic Agents, pubmed-meshheading:21081243-Insulin, pubmed-meshheading:21081243-Insulin Resistance, pubmed-meshheading:21081243-Leptin, pubmed-meshheading:21081243-Male, pubmed-meshheading:21081243-Middle Aged, pubmed-meshheading:21081243-Pilot Projects, pubmed-meshheading:21081243-Postprandial Period, pubmed-meshheading:21081243-Thiazolidinediones
pubmed:year
2011
pubmed:articleTitle
Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study.
pubmed:affiliation
Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. fmagkos@bidmc.harvard.edu
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural